Sexual-Health
Testosterone Cypionate
Test C; Depo-Testosterone; T cypionate; TRT (testosterone replacement therapy)
Androgen / anabolic steroid (FDA-approved); long-acting testosterone ester
This Testosterone Cypionate entry draws on 15 cited sources published 2018 to 2026. The evidence available is graded FDA-Approved on this site's scale. Dosing is reported as described in the literature rather than as guidance. Sources checked .
At a glance
- Class
- Androgen / anabolic steroid (FDA-approved); long-acting testosterone ester
- Drug class
- Sexual-Health
- Structure
- C19 steroid (testosterone) esterified at the 17-beta-OH with cypionic acid (C8 fatty acid); MW ~412 Da. Not a peptide, included as a representative TRT hormone for stack/comparison purposes.
- Route
- IM / SC injection
- Half-life
- ~8 days (cypionate ester)
- Evidence tier
- FDA-Approved
- Availability
- Prescription
- Research depth
- 193 indexed citations →
Mechanism of action
Endogenous androgen replacement: cleaved in vivo to free testosterone, which binds the androgen receptor (AR) and drives transcription of muscle-protein, erythropoiesis, libido, and bone-density gene programs. Aromatisation to oestradiol and 5-alpha-reduction to DHT account for several downstream effects (mood, fat distribution, prostate signal).
Reported areas of research
FDA-approved hypogonadism treatment; restores libido, mood, energy, lean mass, bone density, and red-cell mass in men with confirmed low testosterone; standard-of-care TRT
Items above describe areas studied in published peptide literature, not approved indications. Most peptides catalogued here are not FDA-approved for human use.
Dosage protocols reported in literature
Standard TRT: 100 mg IM/SC weekly (Bhasin Endocrine Society 2018 starting dose, often split twice-weekly to dampen oestradiol swings). Alternate regimens: 50-100 mg/wk or 100-200 mg every 2 weeks per FDA Depo-Testosterone label. Target trough total testosterone 500-900 ng/dL, titrate to symptom relief and labs. Monitor haematocrit, PSA, oestradiol, lipids quarterly first year
Reported research dosing only. This is not a clinical recommendation. Consult a qualified clinician before any human use.
Known concerns and limitations
Erythrocytosis (polycythaemia); HPG suppression and infertility while on therapy; cardiovascular event signal in some cohorts (TRAVERSE 2023 found non-inferiority but not safety in high-risk men); prostate growth and PSA elevation; obstructive sleep apnoea exacerbation; gynaecomastia via aromatisation; contraindicated in suspected/confirmed prostate or breast cancer. Schedule III controlled substance in the US
Frequently asked questions
What dosing is reported for Testosterone Cypionate in research literature?
Published peptide research reports the following dosing approach for Testosterone Cypionate: Standard TRT: 100 mg IM/SC weekly (Bhasin Endocrine Society 2018 starting dose, often split twice-weekly to dampen oestradiol swings). Alternate regimens: 50-100 mg/wk or 100-200 mg every 2 weeks per FDA Depo-Testosterone label. Target trough total testosterone 500-900 ng/dL, titrate to symptom relief and labs. Monitor haematocrit, PSA, oestradiol, lipids quarterly first year. This is a research reference, not a clinical recommendation.
How is Testosterone Cypionate administered in research?
Testosterone Cypionate is administered via the following routes in published studies: IM / SC injection.
What is the reported half-life of Testosterone Cypionate?
The reported half-life of Testosterone Cypionate is ~8 days (cypionate ester).
Is Testosterone Cypionate FDA-approved?
Yes. Testosterone Cypionate is an FDA-approved drug. PeptideHelper.org catalog status: Prescription.
What level of evidence supports Testosterone Cypionate?
The current evidence base for Testosterone Cypionate is best characterised as: FDA-Approved. See the methodology page for the full evidence-tier rubric.
What side effects are reported for Testosterone Cypionate?
Known concerns reported in the literature for Testosterone Cypionate include: Erythrocytosis (polycythaemia); HPG suppression and infertility while on therapy; cardiovascular event signal in some cohorts (TRAVERSE 2023 found non-inferiority but not safety in high-risk men); prostate growth and PSA elevation; obstructive sleep apnoea exacerbation; gynaecomastia via aromatisation; contraindicated in suspected/confirmed prostate or breast cancer. Schedule III controlled substance in the US. Always consult a qualified clinician before any human use.
Is there anyone who should not use Testosterone Cypionate?
Yes. The FDA label for Testosterone Cypionate lists formal contraindications for Testosterone Cypionate: 1. Known hypersensitivity to the drug 2. Males with carcinoma of the breast 3. Males with known or suspected carcinoma of the prostate gland 4. Women who are pregnant 5. Patients with serious cardiac, hepatic or renal disease This is the label's own wording, quoted rather than paraphrased. Always consult a qualified clinician before any human use.
How does Testosterone Cypionate work?
The mechanism of action reported for Testosterone Cypionate in the literature: Endogenous androgen replacement: cleaved in vivo to free testosterone, which binds the androgen receptor (AR) and drives transcription of muscle-protein, erythropoiesis, libido, and bone-density gene programs. Aromatisation to oestradiol and 5-alpha-reduction to DHT account for several downstream effects (mood, fat distribution, prostate signal)..
What is Testosterone Cypionate studied for?
Testosterone Cypionate has been studied in the published literature for: FDA-approved hypogonadism treatment; restores libido, mood, energy, lean mass, bone density, and red-cell mass in men with confirmed low testosterone; standard-of-care TRT. These are areas of research, not established clinical uses unless the compound is FDA-approved for them.
What is Testosterone Cypionate?
Testosterone Cypionate is classified as: Androgen / anabolic steroid (FDA-approved); long-acting testosterone ester. Also known as: Test C; Depo-Testosterone; T cypionate; TRT (testosterone replacement therapy).
Research focus area
All peptides studied for Sexual-Health, ranked by evidence tier and regulatory status.
Primary sources
- FDA Depo-Testosterone (testosterone cypionate) prescribing information
- Bhasin S et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2018. PMID 29562364
- Lincoff AM et al. Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE). N Engl J Med 2023. PMID 37326322
- Bhasin S et al. Testosterone Treatment in Prostate Cancer Survivors With Hypogonadism: A Randomized Clinical Trial. JAMA internal medicine 2026. PMID 42113507
- Farzam K. Individualizing Injectable Testosterone Replacement Therapy in Primary Care: Pharmacokinetics, Symptom Stability, Safety Monitoring, and Injection Frequency. Cureus 2026. PMID 42292725
- Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency [NCT03716739 PHASE2 COMPLETED]
- Goodrum JM et al. Comparing the Stability and Detectability of Testosterone Esters in Capillary Serum, Sodium Fluoride-Containing Plasma, and Dried Blood Spots After Testosterone Ester Administration. Drug testing and analysis 2026. PMID 42219501
- Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients With Low Testosterone [NCT04731376 PHASE1 ACTIVE_NOT_RECRUITING]
- Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer [NCT06305598 PHASE1 ACTIVE_NOT_RECRUITING]
- Ruault C et al. Randomized study of the effects of testosterone administration on severity of asthma in horses. Journal of veterinary internal medicine 2026. PMID 42702362
- Velasco de Cos G et al. Course of Testosterone Levels and Potential Biochemical Biomarkers of Androgenization with a Conservative Protocol of Androgen Hormone Therapy in Transgender Males. Journal of clinical medicine 2026. PMID 42652901
- Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer [NCT07852195 PHASE2/PHASE3 NOT_YET_RECRUITING]
- Safety and Efficacy of Weekly Testosterone Cypionate Auto-Injector in Men With Hypogonadism [NCT07898072 PHASE3 RECRUITING]
- The COSMYC Trial (COmbined Suppression of MYC) [NCT06922318 PHASE2 RECRUITING]
- Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance [NCT07278362 PHASE4 RECRUITING]
Open the full interactive PeptideHelper.org reference to compare peptides side-by-side, evaluate stacks, and explore the catalog.
Spot an error or a missing source on this page? Suggest a correction. Corrections are logged and surfaced in the next review.
Loading interactive view…